Tacrolimus induced pseudogout following allogeneic hematopoietic cell transplant.
Danielle A CeninCraig W FreyerColin B LigonSelina M LugerShannon R McCurdyMary Ellen MartinNoelle V FreyPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Patients on tacrolimus following alloHCT presenting with acute joint pain and erythema should be evaluated for CPPD. Hypomagnesemia secondary to CNIs is likely the precipitating factor for CPPD in this population. Patients can effectively be managed with systemic corticosteroids and/or colchicine, however prolonged duration of treatment and even maintenance may be necessary. Based on the Naranjo Algorithm, CPPD secondary to tacrolimus induced hypomagnesemia is a possible adverse drug event, with a score of 3-4.
Keyphrases
- end stage renal disease
- adverse drug
- ejection fraction
- chronic kidney disease
- drug induced
- machine learning
- bone marrow
- high glucose
- emergency department
- stem cell transplantation
- mesenchymal stem cells
- stem cells
- liver failure
- single cell
- deep learning
- spinal cord injury
- neuropathic pain
- patient reported outcomes
- intensive care unit
- pain management
- hepatitis b virus
- electronic health record
- extracorporeal membrane oxygenation
- replacement therapy
- smoking cessation
- neural network